Head of Department of Soft Tissue/Bone Sarcoma and Melanoma
Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Department of Soft Tissue/Bone Sarcoma and Melanoma
Warsaw, Mazowieckie, Poland
Piotr Rutkowski is Professor of Surgical Oncology at the Maria Sklodowska-Curie National Research Institute of Oncology in Warsaw, Poland.
Dr Rutkowski is the current Head of the Department of Soft Tissue/Bone Sarcoma and Melanoma, the Plenipotentiary of Head Director of Institute for National Oncological Strategy and Clinical Trials at the Maria Sklodowska-Curie National Research Institute of Oncology. He has participated in several investigator-driven trials in melanoma and sarcoma. He is a reviewer for several international scientific journals, as well as a member of the Editorial Board of Annals of Surgical Oncology and European Journal of Surgical Oncology.
Dr Rutkowski is an active member of the EORTC Melanoma Group; EORTC Soft Tissue and Bone Sarcoma Group, where he chaired the Local Treatment Subcommittee and the Membership Committee of the EORTC Board. He is a member of several Polish and international scientific societies (President of Polish Oncological Society, Board member of Polish Society Surgical Oncology, Ex-member of the Board of Directors of the Connective Tissue Oncology Society, member of International Affair Committee of ASCO, Global Curriculum Committee of ESMO). Prof. Rutkowski has authored or co-authored over 500 scientific papers in Polish and international journals (with an impact factor of above 4000, index-H:80, citation index >30000, rewarded Highly Cited Researcher in Clinical Medicine 2021 and 2022), and is co-author of national and international recommendations for sarcoma and melanoma. He is working very closely with national patient advocacy groups for GIST/sarcoma and melanoma, coordinating Polish Sarcoma Group and is Chairman of the Melanoma Academy in Poland. Member of Council of Agency of Medical Research. Chair of Task Group of Ministry of Health, Poland for National Oncological Strategy.
Disclosure information not submitted.
Thursday, November 2, 2023
4:00 PM – 5:30 PM